LaZure Scientific, Inc. was formed in 2006 for the purpose of commercially developing LDAC, a proprietary, preferential, low dose alternating current cancer treatment technology. Using its LDAC technology, the Company has developed an investigational clinical device for early stage prostate cancer treatment. With this device, the Company has completed 17 non-clinical studies, including a GLP safety study, that show the device’s ability to effectively destroy cancer cells, while leaving healthy tissue, nerves and blood vessels in the same treatment volume unharmed. The Company’s first-in-man feasibility studies are currently ongoing in Tbilisi, Georgia and Pretoria, South Africa. A total of 46 patients will be treated in the human studies with the last of the patients scheduled to be treated prior to December 2015.